Such insight is essential to better understand the pathophysiology of metabolic diseases with liver involvement such as type 2 diabetes and GSD I, which are associated with constitutive activation of hepatic ChREBP, glucose, G6P and glycogen imbalances, and increased risk for hepatocellular transformation [24,25]. Here, MLXIPL is linked to metabolic disease.